<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981276</url>
  </required_header>
  <id_info>
    <org_study_id>HSP-PBP</org_study_id>
    <secondary_id>01GM1905</secondary_id>
    <nct_id>NCT03981276</nct_id>
  </id_info>
  <brief_title>Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders</brief_title>
  <acronym>HSP-PBP</acronym>
  <official_title>Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Rebecca Schule</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Neurodegenerative Diseases (DZNE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the clinical spectrum and natural progression of
      Hereditary Spastic Paraplegias (HSP) and related disorders in a prospective multicenter
      natural history study, identify digital, imaging and molecular biomarkers that can assist in
      diagnosis and therapy development and study the genetic etiology and molecular mechanisms of
      these diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a registry-based standardized prospective Natural History
      Study (NHS) in HSPs and related disorders. Participants will be seen annually. At study
      visits a standardized clinical examination will be performed including application of
      clinical rating scales (selection of rating scales may vary depending on the individual
      phenotype and specific genotype); data will be entered into a clinical database (HSP
      Registry; https://www.hsp-registry.net). At all study visits, patients will be asked to
      donate biosamples; biomaterial collection is optional and participants can elect to
      participate in sampling of blood, urine, CSF, and/or a skin biopsy.

      Optionally, additional examinations may be performed including imaging, quantitative movement
      analysis, neuropsychological examinations, analysis of patient or observer reported outcomes
      and OMICS analysis to characterize molecular biomarkers.

      In participants without a genetic diagnosis, next generation sequencing may be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">August 2041</completion_date>
  <primary_completion_date type="Anticipated">August 2039</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Change from baseline of Spastic Paraplegia Rating Scale (SPRS) total score at 2 years</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Disease severity will be assessed by application of the Spastic Paraplegia Rating Scale (SPRS), a clinical rating scale measuring disease severity in Hereditary Spastic Paraplegia (Schüle et al. Neurology 2006). The SPRS contains 13 items, each ranging from 0 to 4 points. The total score is calculated as the sum of all items, yielding a range for the total score between 0 and 52. Hereby, higher SPRS total scores indicate more severe disease.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hereditary Spastic Paraplegia</condition>
  <arm_group>
    <arm_group_label>Primary participant:</arm_group_label>
    <description>Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.
Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary participant/ First or second-degree</arm_group_label>
    <description>First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated healthy control</arm_group_label>
    <description>Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical rating scale to measure disease severity and progression</intervention_name>
    <description>A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.</description>
    <arm_group_label>Primary participant:</arm_group_label>
    <other_name>Spastic Paraplegia Rating Scale (SPRS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Next-Gen Sequencing (NGS)</intervention_name>
    <description>Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics</description>
    <arm_group_label>Primary participant:</arm_group_label>
    <arm_group_label>Secondary participant/ First or second-degree</arm_group_label>
    <arm_group_label>Unrelated healthy control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      optional biosample collection including blood (DNA, serum, plasma, RNA, PBMC), urine, CSF,
      skin biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Probands with a clinical or genetic diagnosis of an HSP and related disorders including
        pre-manifest individuals will be primarily enrolled in this study (primary participants).

        Additionally, unaffected family members of primary participants will be enrolled if they
        are of legal age (&gt;= 18 years) and able to give informed consent (secondary participants).

        Unaffected minors will only be enrolled under special circumstances as detailed in
        paragraph 5.1 (Special Populations - Unaffected minors).

        Lastly, healthy unrelated controls will be enrolled; these are necessary to contrast
        unspecific, gender- or age-related findings to disease specific findings.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  One of the following:

               1. Primary participant: Clinical or genetic diagnosis of HSP or a related disorder

               2. Secondary participant: Unaffected family member (1st or 2nd degree relative) of
                  primary participant (with the above-mentioned restrictions for special
                  populations) able to give informed consent

               3. Unrelated healthy control able to give informed consent

                  AND

          -  Written informed consent

        AND

        - Participants are willing and able to comply with study procedures

        Exclusion criteria:

          -  Missing informed consent of primary or secondary participant/ healthy control/ legal
             representatives

          -  For controls: evidence of a neurodegenerative disease or movement disorders; inability
             to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Schüle, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Schüle, PD Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>85653</phone_ext>
    <email>rebecca.schuele-freyer@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludger Schöls, Prof. Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>85548</phone_ext>
    <email>ludger.schoels@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Amprosi</last_name>
      <phone>+43 512 504 83686</phone>
      <email>matthias.amprosi@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Bösch</last_name>
      <phone>+43 512 504 83686</phone>
      <email>sylvia.boesch@i-med.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvia Bösch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Amprosi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Klockgether</last_name>
      <phone>+49 228 28715726</phone>
      <email>Thomas.Klockgether@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Klockgether, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xenia Kobeleva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Seifert</last_name>
      <phone>+49 9131 85 44751</phone>
      <email>susanne.seifert@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Pia-Marie Pryssok</last_name>
      <phone>+49 9131 85 44751</phone>
      <email>pia-marie.pryssok@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Winkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heiko Gassner, Dr. Phil.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medicine Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylwia Kante</last_name>
      <phone>+49 201 - 7236513</phone>
      <email>sylwia.kante@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Klebe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anja Schadenberg</last_name>
      <phone>+49 551 39 10206</phone>
      <email>aschadenberg@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Michael Sereda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonja Fritzsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Knut Brockmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne van Riesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heike Jacobi</last_name>
      <phone>+49 6221 - 56 - 7510</phone>
      <email>Heike.Jacobi@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Heike Jacobi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maike Dümcke-Zilian</last_name>
      <phone>+49 451 3101 8215</phone>
      <email>maike.duemcke-zilian@neuro.uni-luebeck.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Münchau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurogedenerative Diseases (DZNE) Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Butryn</last_name>
      <phone>+49 391-67-13431</phone>
      <email>michaela.butryn@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Vielhaber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Butryn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmina Al-Tamami</last_name>
      <phone>+49 89 4400 57425</phone>
      <email>jasmina.altamami@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Klopstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florentine Radelfahrt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zacharias Kohl</last_name>
      <phone>+49 941 941 3074</phone>
      <email>zacharias.kohl@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Zacharias Kohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Kamm</last_name>
      <phone>+49 381 4944763</phone>
      <email>christoph.kamm@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Kamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tübingen and German Center for Neurodegenerative Diseases (DZNE) Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Dillmann</last_name>
      <phone>+49 7071 29 85653</phone>
      <email>katrin.dillmann@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Rebecca Schüle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludger Schöls, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingeborg Krägeloh-Mann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion Döbler-Neumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://treathsp.net</url>
    <description>Website of the TreatHSP consortium</description>
  </link>
  <link>
    <url>http://hsp-registry.net</url>
    <description>Website of the HSP Registry</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Rebecca Schule</investigator_full_name>
    <investigator_title>Principal Investigator, Leading Consultant</investigator_title>
  </responsible_party>
  <keyword>Hereditary Spastic Paraplegia</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Genetic etiology</keyword>
  <keyword>Molecular mechanisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

